AB
AB3A.F Sarepta Therapeutics Inc
- Market cap
- EUR 1.58B
- P/E
- 739.0x
- P/B
- 1.23x
- ROE
- 26.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AB3A.F undervalued?
Graham numberThe Graham number of Sarepta Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sarepta Therapeutics Inc fundamental analysis
No fundamental analysis for Sarepta Therapeutics Inc yet.
Sarepta Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed…
Full company profileSarepta Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sarepta Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.42M | 155M | 301M | 381M | 540M | 702M | 933M | 1.24B | 1.90B | 2.20B | 2.02B |
| Gross Profit | 5.29M | 147M | 267M | 324M | 477M | 605M | 793M | 1.09B | 1.58B | 1.36B | 1.42B |
| Operating Income | -264M | -140M | -346M | -522M | -564M | -450M | -536M | -268M | 218M | -658M | 536M |
| EBITDA | - | -34.8M | -317M | -653M | -466M | -317M | -595M | -454M | 317M | -620M | 543M |
| Net Income | -267M | -50.7M | -362M | -715M | -554M | -419M | -703M | -536M | 235M | -713M | 397M |
| EPS | - | -0.78 | -5.09 | -9.51 | -6.98 | -4.81 | -8.00 | -5.73 | 2.43 | -6.80 | 3.70 |
| Balance Sheet | |||||||||||
| Total Assets | 424M | 1.31B | 1.64B | 1.82B | 2.98B | 3.15B | 3.13B | 3.26B | 3.96B | 3.35B | 3.17B |
| Total Liabilities | 87.4M | 519M | 610M | 1.00B | 2.22B | 2.22B | 2.74B | 2.41B | 2.44B | 2.21B | 1.64B |
| Shareholders' Equity | 337M | 789M | 1.03B | 818M | 762M | 928M | 385M | 859M | 1.53B | 1.14B | 1.53B |
| Cash & Short-term Investments | 122M | 600M | 371M | 835M | 1.50B | 2.12B | 967M | 428M | 1.10B | 801M | 473M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -246M | -232M | -389M | -456M | 107M | -443M | -325M | -501M | -206M | -205M | 72.5M |
| Capital Expenditure | 6.87M | 12.0M | 61.2M | 59.6M | 82.2M | 38.5M | 30.8M | 87.3M | 147M | 110M | 13.0M |
| Free Cash Flow | - | -253M | -453M | -519M | 25.3M | -482M | -356M | -588M | -353M | -315M | 59.4M |
| Ratios | |||||||||||
| ROE | -79.4% | -6.4% | -35.1% | -87.4% | -72.7% | -45.1% | -182.7% | -62.4% | 15.4% | -62.5% | 26.0% |
| ROA | -63.0% | -3.9% | -22.0% | -39.2% | -18.6% | -13.3% | -22.5% | -16.4% | 5.9% | -21.3% | 12.5% |
| Net Profit Margin | -4,930.2% | -32.8% | -120.2% | -187.8% | -102.6% | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% | 19.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sarepta Therapeutics Inc dividends
Sarepta Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:6 on Jul 12, 2012.
Who owns Sarepta Therapeutics Inc
- Insiders 4.81%
- Institutions 95.19%
- Public & others 0.00%
- Shares outstanding 107M
- Free float 102M
Sarepta Therapeutics Inc company profile
- Company name
- Sarepta Therapeutics Inc
- Ticker
- AB3A.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 835
- Fiscal year end
- December
- Address
- 215 First Street, Cambridge, MA, United States, 02142
- Phone
- 617 274 4000
- Website
- sarepta.com
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta Therapeutics Inc management
10- Mr. Ian Michael EstepanPresident & COO · born 1976
- Mr. Ryan H. WongExecutive VP & CFO · born 1979
- Ms. Cristin L. Rothfuss J.D.Executive VP, General Counsel & Company Secretary · born 1968
- Mr. Douglas S. Ingram Esq., J.D.Advisor · born 1963
- Dr. Louise R. Rodino-Klapac Ph.D.President of Research & Development and Technical Operations · born 1978
- Dr. Michael E. Severino M.D.CEO & Director · born 1966
- Rachael Potter Ph.D.Chief Scientific Officer
- Tamara ThorntonDirector of Finance, Treasury & Investor Relations
- Ms. Alison NasisiExecutive VP & Chief People Officer
- Dr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy Officer